15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Phenotype and Clinical Outcomes of Titin Cardiomyopathy

      research-article
      , BMBCh a , b , , MSc c , , MSc a , b , , PhD a , b , d , , MBChB, MRCP a , b , , BMBCh a , b , , MBBS, PhD b , , PhD a , b , , MD b , , BSc b , , BSc b , , MSc b , , MSc a , b , , DM b , , MBBS, MD(Res) b , , MBBS, BSc, PhD b , , MD a , b , , PhD a , b , , MD b , , PhD a , b , d , , MD a , b , , PhD a , b , d , e , f ,
      Journal of the American College of Cardiology
      Elsevier Biomedical
      DCM, genetics, CMR, titin, CMR, cardiovascular magnetic resonance, DCM, dilated cardiomyopathy, LGE, late gadolinium enhancement, LMNA, lamin A/C gene, LVMi, indexed left ventricular mass, TTNtv, truncating variant in titin gene

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification.

          Objectives

          The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM.

          Methods

          In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events.

          Results

          Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m 2 reduction; p adjusted = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv +/− groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82).

          Conclusions

          In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis.

          Central Illustration

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

          Risk stratification of patients with nonischemic dilated cardiomyopathy is primarily based on left ventricular ejection fraction (LVEF). Superior prognostic factors may improve patient selection for implantable cardioverter-defibrillators (ICDs) and other management decisions. To determine whether myocardial fibrosis (detected by late gadolinium enhancement cardiovascular magnetic resonance [LGE-CMR] imaging) is an independent and incremental predictor of mortality and sudden cardiac death (SCD) in dilated cardiomyopathy. Prospective, longitudinal study of 472 patients with dilated cardiomyopathy referred to a UK center for CMR imaging between November 2000 and December 2008 after presence and extent of midwall replacement fibrosis were determined. Patients were followed up through December 2011. Primary end point was all-cause mortality. Secondary end points included cardiovascular mortality or cardiac transplantation; an arrhythmic composite of SCD or aborted SCD (appropriate ICD shock, nonfatal ventricular fibrillation, or sustained ventricular tachycardia); and a composite of HF death, HF hospitalization, or cardiac transplantation. Among the 142 patients with midwall fibrosis, there were 38 deaths (26.8%) vs 35 deaths (10.6%) among the 330 patients without fibrosis (hazard ratio [HR], 2.96 [95% CI, 1.87-4.69]; absolute risk difference, 16.2% [95% CI, 8.2%-24.2%]; P < .001) during a median follow-up of 5.3 years (2557 patient-years of follow-up). The arrhythmic composite was reached by 42 patients with fibrosis (29.6%) and 23 patients without fibrosis (7.0%) (HR, 5.24 [95% CI, 3.15-8.72]; absolute risk difference, 22.6% [95% CI, 14.6%-30.6%]; P < .001). After adjustment for LVEF and other conventional prognostic factors, both the presence of fibrosis (HR, 2.43 [95% CI, 1.50-3.92]; P < .001) and the extent (HR, 1.11 [95% CI, 1.06-1.16]; P < .001) were independently and incrementally associated with all-cause mortality. Fibrosis was also independently associated with cardiovascular mortality or cardiac transplantation (by fibrosis presence: HR, 3.22 [95% CI, 1.95-5.31], P < .001; and by fibrosis extent: HR, 1.15 [95% CI, 1.10-1.20], P < .001), SCD or aborted SCD (by fibrosis presence: HR, 4.61 [95% CI, 2.75-7.74], P < .001; and by fibrosis extent: HR, 1.10 [95% CI, 1.05-1.16], P < .001), and the HF composite (by fibrosis presence: HR, 1.62 [95% CI, 1.00-2.61], P = .049; and by fibrosis extent: HR, 1.08 [95% CI, 1.04-1.13], P < .001). Addition of fibrosis to LVEF significantly improved risk reclassification for all-cause mortality and the SCD composite (net reclassification improvement: 0.26 [95% CI, 0.11-0.41]; P = .001 and 0.29 [95% CI, 0.11-0.48]; P = .002, respectively). Assessment of midwall fibrosis with LGE-CMR imaging provided independent prognostic information beyond LVEF in patients with nonischemic dilated cardiomyopathy. The role of LGE-CMR in the risk stratification of dilated cardiomyopathy requires further investigation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance.

            We used state of the art CMR to define ranges for normal left ventricular volumes and systolic/diastolic function normalized to the influence of gender, body surface area and age. New CMR normalized ranges were modeled and displayed in graphical form for clinical use, with normalization for body surface area, gender, and age. The determination of normality, or the severity of abnormality, depends on the use of the appropriate reference ranges normalized to all 3 variables. These novel data have particular importance for clinical practice and clinical trials using CMR.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing.

              Dilated cardiomyopathy is characterized by substantial locus, allelic, and clinical heterogeneity that necessitates testing of many genes across clinically overlapping diseases. Few studies have sequenced sufficient individuals; thus, the contributions of individual genes and the pathogenic variant spectrum are still poorly defined. We analyzed 766 dilated cardiomyopathy patients tested over 5 years in our molecular diagnostics laboratory.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Am Coll Cardiol
                J. Am. Coll. Cardiol
                Journal of the American College of Cardiology
                Elsevier Biomedical
                0735-1097
                1558-3597
                31 October 2017
                31 October 2017
                : 70
                : 18
                : 2264-2274
                Affiliations
                [a ]National Heart Lung Institute, Imperial College London, London, United Kingdom
                [b ]Cardiovascular Research Centre, Royal Brompton Hospital, London, United Kingdom
                [c ]Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
                [d ]Medical Research Council London Institute of Medical Sciences, Imperial College London, London, United Kingdom
                [e ]National Heart Centre, Singapore
                [f ]Duke-NUS Medical School, Singapore
                Author notes
                [] Address for correspondence: Dr. Stuart A. Cook, National Heart Centre Singapore, 5 Hospital Drive, Singapore 169609.National Heart Centre Singapore5 Hospital DriveSingapore 169609 stuart.cook@ 123456singhealth.com.sg
                Article
                S0735-1097(17)39473-1
                10.1016/j.jacc.2017.08.063
                5666113
                29073955
                a15a3a29-dde0-445c-9589-78484fd2271c
                © 2017 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 June 2017
                : 4 August 2017
                : 30 August 2017
                Categories
                Article

                Cardiovascular Medicine
                dcm,genetics,cmr,titin,cmr, cardiovascular magnetic resonance,dcm, dilated cardiomyopathy,lge, late gadolinium enhancement,lmna, lamin a/c gene,lvmi, indexed left ventricular mass,ttntv, truncating variant in titin gene

                Comments

                Comment on this article